Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Decline in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 132,900 shares, a drop of 7.9% from the November 15th total of 144,300 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average trading volume of 232,800 shares, the short-interest ratio is presently 0.6 days.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lowered their price target on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Monday.

Alzamend Neuro Stock Up 2.5 %

Shares of NASDAQ:ALZN opened at $1.22 on Tuesday. The company has a 50 day moving average of $1.45 and a 200-day moving average of $2.63. Alzamend Neuro has a twelve month low of $1.06 and a twelve month high of $15.06.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.